- US Vaccines Current Procedural Terminology Codes
- Vaccines CPT Codes
- US Vaccine
- FDA Vaccine
- Vaccine CPT
Vaccines Current Procedural Terminology Codes
The Vaccines Current Procedural Terminology Codes database cross-references Current Procedural Terminology (CPT) codes that are related to vaccines, toxoids and immune globulins with their corresponding CVX codes. The goal of the table is to support mapping of CPT codes to CVX codes in systems that receive CPT codes as part of an electronic data exchange.
Get The Data
- ResearchNon-Commercial, Share-Alike, Attribution Free Forever
- CommercialCommercial Use, Remix & Adapt, White Label Log in to download
The goal of the vaccines current procedural terminology codes database is to support mapping of CPT codes to CVX codes in systems that receive CPT codes as part of an electronic data exchange.
The CVX and/or NDC code systems are highly recommended when exchanging immunization data, but if a sending system must use CPT codes, this table may be used by the receiving system to translate the CPT code to the single best CVX code equivalent.
In all cases, the code utilized, be it NDC, CVX or CPT, should be the most specific and granular representation possible of the vaccine given. Where only a single vaccine exists, the CPT code is mapped to that vaccine specific CVX code. However, in many cases, a single CPT code could be used with multiple vaccines utilizing different CVX codes. In this situation, the CPT code is mapped to the “unspecified formulation” CVX code because it is not possible to infer a specific vaccine formulation from the CPT code alone.
This table is not intended to support mapping from CVX to CPT nor to be a definitive source for CPT codes. Practices must approach billing for vaccines (selection of a CPT code for a given administration) independently from recording and reporting the most specific vaccine codes to an IIS or other clinical trading partners. Active CPT codes, inactive CPT codes and pre-release CPT codes are included. Every effort is made to keep the codes current.
About this Dataset
John Snow Labs; National Center for Immunization and Respiratory Diseases;
|Source License URL|
|Source License Requirements||
US Vaccine, FDA Vaccine, Vaccine CPT
US Vaccines Current Procedural Terminology Codes, Vaccines CPT Codes
|CPT_Code||Vaccine Current Procedural Terminology||integer||level : Nominalrequired : 1|
|CPT_Description||Current Procedural Terminology description||string||required : 1|
|CVX_Short_Description||Short description of CVX||string||required : 1|
|CVX_Code||CVX for unit of sale NOTE that for some vaccines that have separate vaccine components, the CVX will map to the combined vaccine.||integer||level : Nominalrequired : 1|
|CPT_Comment||Current Procedural Terminology comments||string||-|
|Last_Updated||The date this record was last updated||date||-|
|CPT_Code_ID||Current Procedural Terminology code identifier||string||-|
|CPT Code||CPT Description||CVX Short Description||CVX Code||CPT Comment||Last Updated||CPT Code ID|
|90281||Immune globulin (Ig), human, for intramuscular use||IG||86||2020-04-14||169|
|90283||Immune globulin (IgIV), human, for intravenous use||IGIV||87||2020-04-14||170|
|90287||Botulinum antitoxin, equine, any route||botulinum antitoxin||27||2017-02-28||171|
|90291||Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use||CMVIG||29||2020-04-14||172|
|90296||Diphtheria antitoxin, equine, any route||diphtheria antitoxin||12||2017-02-28||173|
|90371||Hepatitis B immune globulin (HBIg), human, for intramuscular use||HBIG||30||2020-04-14||174|
|90375||Rabies immune globulin (RIg), human, for intramuscular and/or subcutaneous use||RIG||34||2020-04-14||175|
|90376||Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use||RIG||34||2020-04-14||176|
|90378||Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each||RSV-MAb||93||2020-04-14||177|
|90379||Respiratory syncytial virus immune globulin (RSV-IgIV), human, for intravenous use||RSV-IGIV||71||2017-02-28||178|